FDA approval for REGN Pasatru™ in adult FOP patients
Regeneron (REGN) says Pasatru™ (garetosmab-grts) is the first and only FDA-approved treatment shown to reduce new heterotopic ossification lesions and clinician-assessed flare-ups in a placebo-controlled adult FOP trial.